Tohoku University Technology: HDAC and PI3K inhibitor for cancer treatment: T11-036
low molecular weight compound with anti-cancer activity for nano-molarity
PI3K / AKT pathway is known as the major signaling pathway involved in survival and proliferation of cells. This is also known as the therapeutic target for cancer because this is aberrantly-activated for various cancer cells. Therefore, the inventors screened compounds with PI3K inhibitory activity from hundreds of compound. The results show that FK228 (a.k.a. Istodax(R)), HDAC inhibitor, and its analogs have PI3K inhibitory activity.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
